Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma

Blood

Volumn 122, Issue 6, 2013, Pages 958-968

  McDonnell, Scott R P ^a   Hwang, Steven R ^a   Rolland, Delphine ^a   Murga Zamalloa, Carlos ^a   Basrur, Venkatesha ^a   Conlon, Kevin P ^a   Fermin, Damian ^a   Wolfe, Thomas ^a   Raskind, Alexander ^a   Ruan, Chunhai ^a   Jiang, Jian Kang ^b   Thomas, Craig J ^b   Hogaboam, Cory M ^a   Burant, Charles F ^a   Elenitoba Johnson, Kojo S J ^a   Lim, Megan S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; PROTEIN TYROSINE KINASE; PYRUVATE KINASE; PYRUVATE KINASE M2; TYROSINE KINASE NUCLEOPHOSMIN ANAPLASTIC LYMPHOMA KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; MEMBRANE PROTEIN; P80(NPM ALK) PROTEIN; P80(NPM-ALK) PROTEIN; THYROID HORMONE; THYROID HORMONE BINDING PROTEINS; THYROID HORMONE-BINDING PROTEINS;

AEROBIC GLYCOLYSIS; ANAPLASTIC LARGE CELL LYMPHOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMASS PRODUCTION; CARCINOGENESIS; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; IN VIVO STUDY; METABOLIC ACTIVITY ASSAY; METABOLIC FLUX ANALYSIS; METABOLOMICS; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; HUMAN; LARGE CELL LYMPHOMA; METABOLISM; PHOSPHORYLATION; PROTEOMICS; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MEMBRANE PROTEINS; METABOLOMICS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTEOMICS; SUBSTRATE SPECIFICITY; THYROID HORMONES;

EID: 84886923713     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-482026     Document Type: Article

References (39)

1. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007;110(7): 2259-2267.
2. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin’s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997;17(4):2312-2325.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
4. Janoueix-Lerosey I, Lequin D, Brugières L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455(7215):967-970.
5. Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776-2780.
6. Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004;23(32): 5426-5434.
7. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-g to mediate its mitogenicity. Mol Cell Biol. 1998;18(12):6951-6961.
8. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene. 2004;23(15):2617-2629.
9. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61(5):2194-2199.
10. McDonnell SRP, Hwang SR, Basrur V, et al. NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis. Oncogene. 2012;31(32):3733-3740.
11. Lim MS, Carlson ML, Crockett DK, et al. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood. 2009;114(8):1585-1595.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
13. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6): 519-530.
14. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27: 441-464.
15. Ott GR, Tripathy R, Cheng M, et al. Discovery of a potent Inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010;1(9):493-498.
16. Anastasiou D, Yu Y, Israelsen WJ, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8(10):839-847.
17. Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97):ra73.
18. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623-629.
19. Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13.
20. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
21. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012;40(Web Server issue):W127-W133.
22. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 2009;37(Web Server issue):W652-W660.
23. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40(Database issue): D109-D114.
24. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999; 27(1):29-34.
25. Maehara Y, Anai H, Tamada R, Sugimachi K. The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol. 1987;23(3): 273-276.
26. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230-233.
27. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007; 6(12 Pt 1):3314-3322.
28. Lardy HA, Connelly JL, Johnson D. Antibiotics as tools for metabolic studies. II. Inhibition of phosphoryl transfer in mitochondria by oligomycin and aurovertin. Biochemistry. 1964;3(12): 1961-1968.
29. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008; 452(7184):181-186.
30. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997;94(13):6658-6663.
31. Fan J, Hitosugi T, Chung TW, et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol. 2011;31(24): 4938-4950.
32. Hitosugi T, Fan J, Chung TW, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell. 2011;44(6):864-877.
33. Hitosugi T, Zhou L, Elf S, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell. 2012; 22(5):585-600.
34. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49): 19345-19350.
35. Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, Thompson CB. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA. 2012;109(18):6904-6909.
36. Kung C, Hixon J, Choe S, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol. 2012;19(9):1187-1198.
37. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66(13):6589-6597.
38. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents—a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133(2):176-182.
39. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA. 2011;108(18):7535-7540.